Caroline Vu

Cooley advised Kite Pharma, a Gilead company, dedicated to developing active immunotherapies, in the formation of a clinical collaboration with Humanigen, Inc. to conduct a Phase ½ study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The goal of this collaboration is to determine the effect of lenzilumab on the clinical profile of Yescarta. Financial terms were not disclosed. Cooley special counsel Caroline Vu advised Kite.

Cooley advised Kite Pharma, a Gilead company, dedicated to developing active immunotherapies, in its clinical collaboration with Kiniksa Pharmaceuticals to conduct a Phase 2, multicenter study of mavrilimumab, an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma. The goal of this collaboration is to determine the effect of mavrilimumab on the clinical profile of Yescarta. Financial terms were not disclosed. Cooley special counsel Caroline Vu advised Kite.

Cooley advised Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, on its definitive agreement with ACELYRIN to merge in an all-stock transaction.